依拉普利对近期临床分离革兰氏阳性菌的抗菌活性和杀菌活性
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
作者信息
Sader Helio S, Fritsche Thomas R, Jones Ronald N
机构信息
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
出版信息
Antimicrob Agents Chemother. 2009 May;53(5):2171-5. doi: 10.1128/AAC.00129-09. Epub 2009 Mar 16.
Abstract
The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA.
摘要
新型二氨基嘧啶衍生物依拉普明的体外活性针对在美国和欧洲收集的5937株近期革兰氏阳性临床分离株进行了评估。依拉普明对测试的金黄色葡萄球菌（包括耐甲氧西林金黄色葡萄球菌[MRSA]）、β溶血性链球菌属和粪肠球菌菌株表现出强效活性。此外，依拉普明对所有测试的金黄色葡萄球菌菌株，包括MRSA，均表现出杀菌活性。
相似文献
1
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Antimicrob Agents Chemother. 2009 May;53(5):2171-5. doi: 10.1128/AAC.00129-09. Epub 2009 Mar 16.
2
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
Diagn Microbiol Infect Dis. 2018 Apr;90(4):329-334. doi: 10.1016/j.diagmicrobio.2017.12.001. Epub 2017 Dec 7.
3
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10.
4
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
Diagn Microbiol Infect Dis. 2007 Apr;57(4):459-65. doi: 10.1016/j.diagmicrobio.2006.10.007. Epub 2007 Jan 19.
5
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Int J Antimicrob Agents. 2007 Aug;30(2):143-9. doi: 10.1016/j.ijantimicag.2007.03.015. Epub 2007 May 24.
6
Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02239-18. Print 2019 Apr.
7
Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.
8
In vitro activity of teicoplanin against gram-positive cocci.
Pathol Biol (Paris). 2000 Oct;48(8):792-5.
9
Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
Diagn Microbiol Infect Dis. 2020 May;97(1):115013. doi: 10.1016/j.diagmicrobio.2020.115013. Epub 2020 Feb 5.
10
In vitro bactericidal activity of iclaprim in human plasma.
Antimicrob Agents Chemother. 2009 Oct;53(10):4542-4. doi: 10.1128/AAC.00766-09. Epub 2009 Aug 3.
引用本文的文献
1
Transcriptional Response of to Cinnamaldehyde Treatment.
J Microbiol Biotechnol. 2024 Mar 28;34(3):538-546. doi: 10.4014/jmb.2311.11043. Epub 2023 Dec 25.
2
Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.
J Antimicrob Chemother. 2023 May 3;78(5):1201-1210. doi: 10.1093/jac/dkad063.
3
Efficacy and Safety of Iclaprim for the Treatment of Skin Structures and Soft Tissue Infections: A Methodological Framework.
Front Pharmacol. 2022 Jul 19;13:932688. doi: 10.3389/fphar.2022.932688. eCollection 2022.
4
Evaluation of activity of iclaprim in combination with other antimicrobials against pulmonary pathogens: a pilot study.
Access Microbiol. 2019 May 20;1(3):e000027. doi: 10.1099/acmi.0.000027. eCollection 2019.
5
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.
Microorganisms. 2020 Jan 30;8(2):191. doi: 10.3390/microorganisms8020191.
6
Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02239-18. Print 2019 Apr.
7
Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):409-412. doi: 10.1007/s10096-018-3440-2. Epub 2018 Nov 27.
8
Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00236-18. Print 2018 Aug.
9
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02580-17. Print 2018 May.
10
Activity of Iclaprim against Methicillin-Resistant Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.
Can J Infect Dis Med Microbiol. 2017;2017:3948626. doi: 10.1155/2017/3948626. Epub 2017 Dec 17.
本文引用的文献
1
Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
J Antimicrob Chemother. 2009 Apr;63(4):687-98. doi: 10.1093/jac/dkp024. Epub 2009 Feb 11.
2
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Curr Opin Investig Drugs. 2008 Feb;9(2):210-25.
3
Treatment challenges in the management of complicated skin and soft-tissue infections.
Clin Microbiol Infect. 2008 Mar;14 Suppl 2:17-25. doi: 10.1111/j.1469-0691.2008.01922.x.
4
Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.
Infection. 2008 Feb;36(1):85-7. doi: 10.1007/s15010-007-7220-7. Epub 2007 Dec 28.
5
Iclaprim.
Expert Opin Investig Drugs. 2007 Sep;16(9):1441-8. doi: 10.1517/13543784.16.9.1441.
6
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Chemother. 2007 Oct;60(4):788-94. doi: 10.1093/jac/dkm258. Epub 2007 Jul 10.
7
Dihydrofolate reductase inhibitors as antibacterial agents.
Biochem Pharmacol. 2006 Mar 30;71(7):941-8. doi: 10.1016/j.bcp.2005.10.052. Epub 2005 Dec 13.
8
Practice guidelines for the diagnosis and management of skin and soft-tissue infections.
Clin Infect Dis. 2005 Nov 15;41(10):1373-406. doi: 10.1086/497143. Epub 2005 Oct 14.
9
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
10
Newer treatment options for skin and soft tissue infections.
Drugs. 2004;64(15):1621-42. doi: 10.2165/00003495-200464150-00002.
Zotero 插件